New research indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional lifestyle regimens.
Research printed in a prominent medical journal points out that while obese people can lose about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Users buying such medications should be cognizant of the potential of rapid weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a return to starting mass within about 18 months.
Weighing Treatments
The analysis, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team note that individuals who shed pounds through lifestyle changes alone typically experience a slower weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Rebound
Doctors suggest the mechanism of the drugs explains the amplified regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its own natural hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals contend that, considering the likelihood of weight regain, the treatment might need to be ongoing.
This view is echoed by pharmaceutical companies, who note that the findings "highlight the long-term nature of excess weight," similar to managing diseases like diabetes.
User Experiences
Users who have discontinued the jabs explain a powerful return of hunger.
"It was like a switch flipping and you're instantly ravenous," said a patient.
This difficulty is exacerbated if individuals have not developed permanent lifestyle or habit modifications during therapy.
Significant Adoption
Figures show that a significant number of people in the UK have used these injections in the past year, with interest remaining high.
- Adoption is higher among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone cure and lasting health benefits hinges on ongoing lifestyle changes.
